| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/19/2006 | US20060014740 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof |
| 01/19/2006 | US20060014739 Androgen receptor modulators and method of treating disease using the same |
| 01/19/2006 | US20060014737 Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors |
| 01/19/2006 | US20060014736 Phenothiazine kinesin inhibitors |
| 01/19/2006 | US20060014735 immunoglobulins; affinity chromatography |
| 01/19/2006 | US20060014734 Immediate release pharmaceutical formulation |
| 01/19/2006 | US20060014733 Histamine-3 agonists and antagonists |
| 01/19/2006 | US20060014732 Use of targeted oxidative therapeutic formulation in treatment of burns |
| 01/19/2006 | US20060014731 Analogs of benzoquinone-containing ansamycins and methods of use thereof |
| 01/19/2006 | US20060014730 Ansamycin formulations and methods for producing and using same |
| 01/19/2006 | US20060014729 Compounds and their preparation for the treatment of Alzheimer's disease by inhibiting beta-amyloid peptide production |
| 01/19/2006 | US20060014728 Hormone replacement therapy |
| 01/19/2006 | US20060014727 Angiogenic compounds and uses thereof |
| 01/19/2006 | US20060014726 Derivatives of cyclic1, 3- propanediol phosphate and their action in differentiation therapy |
| 01/19/2006 | US20060014725 6-(1-benzyl-3-pentyl-1H-indol-2-yl)-1-bromo-2-naphthyl 1H-tetraazol-5-ylmethyl ether; useful in treating stroke associated with or resulting from atrial fibrillation; thrombolytic agents for prohylaxis of cardiovascular disorders |
| 01/19/2006 | US20060014723 Anti-parasitic uses of borinic acid complexes |
| 01/19/2006 | US20060014722 Per (3,6-anhydro) cyclodextrin derivatives, their preparation and use thereof for separating ions, in particular chromium and manganese anions |
| 01/19/2006 | US20060014721 Providing at least one oxidized-etherified cellulose derivative selected from the group consisting of water-soluble methylcellulose, ethylcellulose, hydroxyethylcellulose and salts of carboxymethylcellulose, forming the oxidized-etherified cellulose derivative into the medical and treatment products |
| 01/19/2006 | US20060014720 Can be implanted for therapy of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor |
| 01/19/2006 | US20060014719 Method for treating neurodegenerative diseases |
| 01/19/2006 | US20060014718 oversulfation of epiK-N sulfate to obtain an epiK5-amine-O-oversulfate with very high sulfation degree which by subsequent N-sulfation provides new epiK5-N,O-oversulfate-derivatives; free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field |
| 01/19/2006 | US20060014717 Therapeutic compositions for use in prophylaxis or treatment of diarrheas |
| 01/19/2006 | US20060014716 Methods and compositions for protecting and treating muscarinic receptors by administering a pyrophosphate analog to a subject exposed to bacterial, fungal, viral, prion or algal infection |
| 01/19/2006 | US20060014709 Drug or cosmetic |
| 01/19/2006 | US20060014708 2,6-Diaminopyridine derivatives |
| 01/19/2006 | US20060014707 Sixteen-member macrolide antiinfective agents |
| 01/19/2006 | US20060014706 treating constipation in a patient with 8,9-didehydro-N-demethyl-9-deoxo-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-11-oxoerythromycin; unlike a laxative |
| 01/19/2006 | US20060014705 Compositions and methods for selectively activating human sirtuins |
| 01/19/2006 | US20060014704 Compounds and their preparation for the treatment of Alzheimer's disease by inhibiting beta-amyloid peptide production |
| 01/19/2006 | US20060014703 Promoting bactericidal and fungicidal activity by applying a cationic surfactant mixture , non-irritating to the skin and eyes; cationic conditioner useful in hair and skin care products; cosmetics |
| 01/19/2006 | US20060014702 Antimicrobial agent |
| 01/19/2006 | US20060014701 Novel amide derivatives as growth hormone secretagogues |
| 01/19/2006 | US20060014700 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies |
| 01/19/2006 | US20060014698 Nebulized pharmaceutical compositions for the treatment of bronchial disorders |
| 01/19/2006 | US20060014695 Hpma-polyamine conjugates and uses therefore |
| 01/19/2006 | US20060014689 And the C-natriuretic peptide hormone; antiproliferative agents; pancreatic cancer |
| 01/19/2006 | US20060014688 Methods of inhibiting tumor cell proliferation |
| 01/19/2006 | US20060014683 Procoagulant protein comprising polypeptide with amino acid substitutions; resistant to activated protein C; von Willebrand factor binding site deleted and thrombin cleavage site is mutated; treating hemophilia |
| 01/19/2006 | US20060014681 Three-dimensional structure of complement receptor type 2 and uses thereof |
| 01/19/2006 | US20060014679 Drug screening; diabetes, obesity, hyperlipemia, arteriosclerosis, hypertension, cardiovascular disorders |
| 01/19/2006 | US20060014677 Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| 01/19/2006 | US20060014672 Tumor specific oligosaccharide epitopes and use thereof |
| 01/19/2006 | US20060014665 Therapeutic agent |
| 01/19/2006 | US20060014290 Reducing or inhibiting a biofilm by modulating expression of a cysB gene present in a Gram-negative bacteria cell capable of biofilm formation; reducing infections |
| 01/19/2006 | US20060014286 Ligand-controlled regulation of endogenous gene expression |
| 01/19/2006 | US20060014285 Methods and compositions for inhibiting biofilms |
| 01/19/2006 | US20060014256 Sodium chondroitin sulfate, chondroitin-sulfate-containing material and processes for producing the same |
| 01/19/2006 | US20060014243 Human G-protein chemokine receptor HSATU68 |
| 01/19/2006 | US20060014242 Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
| 01/19/2006 | US20060014216 Prophylaxis, therapy of Alzheimer's disease; using phenothiazine compound such as methylene blue |
| 01/19/2006 | US20060014204 Methods of inducing formation of functional and organized lymphatic vessels |
| 01/19/2006 | US20060014165 Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
| 01/19/2006 | US20060014157 Sensitivity test to predict efficacy of anti-cancer therapies |
| 01/19/2006 | US20060013905 Anti-inflammatory compositions for treating multiple sclerosis |
| 01/19/2006 | US20060013904 Treatment method comprising administering feverfew to oral mucosal tissues in solid or semi-solid form |
| 01/19/2006 | US20060013902 Pharmaceutical products for treating neoplastic disease and inflammation |
| 01/19/2006 | US20060013901 Compositions comprising flavonoids and tocotrienols and methods thereof |
| 01/19/2006 | US20060013899 Topical compositions for treatment of skin disorders and methods of use thereof |
| 01/19/2006 | US20060013897 Compositions for cancer therapy saponins or sapogenins |
| 01/19/2006 | US20060013896 Methods of treating acute pain using diclofenac |
| 01/19/2006 | US20060013895 Use of a composition and a cleaning tablet containing said composition for disinfecting purposes |
| 01/19/2006 | US20060013893 Bisphosphonates inorganic carriers |
| 01/19/2006 | US20060013892 Administration of amino acid chelates for reduction in alcohol dependency |
| 01/19/2006 | US20060013891 increase water solubility with two co-grinding auxiliary substances, one is amino acid and one is ammonium glycyrrhizate; beeswax with greater bioavailability; as immunostimulants, bactericide and bacteriostatic activities, viricide and mycostatic activities, antiinflammatory agent, wound healing agent |
| 01/19/2006 | US20060013888 using monoterpenes such as limonene; encapsulation; soft capsules |
| 01/19/2006 | US20060013887 Delayed release carnitine |
| 01/19/2006 | US20060013884 Humidity-dependent antibacterial powdery composition, process for producing the same, humidity-dependent antibacterial food storing article and method of storing food |
| 01/19/2006 | US20060013880 Formulation stabilizer for proton pump inhibitors |
| 01/19/2006 | US20060013877 Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same |
| 01/19/2006 | US20060013875 Combination immediate release controlled release levodopa/carbidopa dosage forms |
| 01/19/2006 | US20060013874 Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one |
| 01/19/2006 | US20060013873 Bioadhesive dosage form of steroids |
| 01/19/2006 | US20060013872 Pharmaceutical compositions comprising ibuprofen and domperidone |
| 01/19/2006 | US20060013871 Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution |
| 01/19/2006 | US20060013870 Pharmaceutical compositions of hops resins |
| 01/19/2006 | US20060013869 Electrospun amorphous pharmaceutical compositions |
| 01/19/2006 | US20060013868 Controlled release preparation |
| 01/19/2006 | US20060013866 Transdermal drug delivery formulations with optimal amounts of vasodilators therein |
| 01/19/2006 | US20060013865 Transdermal patch for external use comprising fentanyl |
| 01/19/2006 | US20060013864 Transmucosal pharmacuetical administration form |
| 01/19/2006 | US20060013861 Functional foods comprising flavonoids and tocotrienols and methods thereof |
| 01/19/2006 | US20060013860 Anticancer agents; side effect reduction |
| 01/19/2006 | US20060013858 Fludrocortisone treatment for hearing loss |
| 01/19/2006 | US20060013852 Use of organic compounds |
| 01/19/2006 | US20060013841 Skin treatment |
| 01/19/2006 | US20060013836 Dissolving ixabepilone in tert-butanol and water, and then vacuum drying to lypophilize; 7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-7-oxabicyclo[14.1.0]heptadecane-5,9-dione is ixabepilone |
| 01/19/2006 | US20060013835 Longitudinal body with polymeric coating; triamcinolone acetonide; drug delivery to eye |
| 01/19/2006 | US20060013834 Room temperature stable aqueous liquid pharmaceutical composition |
| 01/19/2006 | US20060013829 Nucleic acid segments; coding zones; genetic engineered cells |
| 01/19/2006 | US20060013820 Antigen delivery vectors and constructs |
| 01/19/2006 | US20060013819 Therapy of platinum-resistant cancer |
| 01/19/2006 | US20060013814 Methods for preventing pressure-induced apoptotic neural-cell death |
| 01/19/2006 | US20060013811 Methods of treating IgE-associated disorders and compositions for use therein |
| 01/19/2006 | US20060013801 Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity |
| 01/19/2006 | US20060013799 Multimeric VLA-4 antagonists comprising polymer moieties |
| 01/19/2006 | US20060013798 Bis-quaternary ammonium salt corrosion inhibitors |
| 01/19/2006 | US20060013797 N-maleimidyl polymer derivatives |
| 01/19/2006 | US20060013796 Hair and/or scalp treatment composition |
| 01/19/2006 | US20060013786 Skin preparation for external use |
| 01/19/2006 | US20060013779 synergistic combination such as sodium lauryl sulfate; chewing gum, a confectionary, a lozenge, a compressed tablet, and an edible film |